Skip to main content
Explore URMC

menu

Melanoma: Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery

Research Question:
Will receiving dabrafenib and trametinib with a break in treatment extend the time before your cancer gets worse?

Basic Study Information

Purpose:
This study will allow the researchers to know whether a break in treatment is better, the same, or worse than continuous treatment of dabrafenib and trametinib. To be better, the break in treatment approach should extend the time before cancer gets worse by about 4 to 6 months compared to the continuous treatment approach.

Location: University of Rochester Medical Center
Study Web URL:  https://clinicaltrials.gov/ct2/show/NCT02196181?term=SWOG+1320&rank=2
Study Reference #: CMEL-14114

Lead Researcher (Principal Investigator)

Lead Researcher: Deepak Sahasrabudhe, MD

Study Contact Information

Study Coordinator: Park Bogan
Phone: (585) 276-4415
Email: Park_Bogan@URMC.Rochester.edu

Additional Study Details

Learn More About These Conditions

More information about Melanoma

Return to Search